Alira Health Starts a New Collaboration with Mark Inigo Jones on Parallel Trade Management

News
Published on:
August 29, 2020

BOSTON, USA – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, is pleased to announce a new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products. Mark brings his extensive knowledge, implementation, and operational experience in effective strategies for parallel trade management initiatives to the firm’s Market Access practice and Parallel Trade practice. The firm’s clients, which includes over 50% of the top 100 pharmaceutical companies, will benefit from this enhanced service offering, which aligns closely with the firm’s market access, pricing, and reimbursement services.

Shaped on best practices developed through his years at Novartis, Mark’s collaboration with Alira Health rounds out a new team focused on supporting clients in increasing profitability and protecting brand reputation through dedicated initiatives for effective parallel trade management.  Using an innovative, data-driven approach, the Alira Health team has extensive operational experience and a record of achievement in supporting clients as they develop and implement successful EU-compliant distribution strategies. A cornerstone of Alira Health’s Parallel Trade practice is to help companies develop their internal capabilities in effective parallel trade corporate governance.

Previously, Mark was the Head of European Trade at Novartis, where he developed and implemented the corporate strategy that lead to the largest reductions in parallel trade of any pharmaceutical peer company. During his time at Novartis, Mark managed portfolios for Alcon and GSK Oncology, where he achieved an increase of the profitability of the brands up to 30 % within 12 months of taking responsibility for their distribution.

Mark holds a variety of master’s degrees in related fields, including EU Competition Law from Kings College London, Health Economics from the London School of Economics, and Finance from The London School of Business. He has also lectured on Parallel Trade at the European Center of Pharmaceutical Medicine course at the University of Basel.

For more information about Alira Health’s Parallel Trade services

Click here

Related news

Multimedia May 26, 2023
Webinar on Advancing Patient Engagement in the Medical Device / MedTech Industry
Engaging with patients, including their caregivers and advocates, is crucial during the planning and execution of clinical trials.
Medical Devices MedTech Patient Engagement
Blog May 17, 2023
Introduction to Patient Engagement in MedTech in the U.S.
Check out these key takeaways from our Playbook for Patient Engagement in MedTech in the U.S. and access the playbook download.
MedTech Patient Engagement USA
Events April 26, 2023
MedTech Forum 2023
We are excited to share that we will be sponsoring and speaking at MedTech Forum 2023. The MedTech Forum is the largest health and medical technology industry conference in Europe and(...)
MedTech Real-World Evidence (RWE)
Publications April 25, 2023
Comprehensive Guide to the Content of Integrated Summaries of Efficacy and Safety (ISE/ISS)
Read this to discover the content of Integrated Summaries of Efficacy and Safety (ISE/ISS).
MedTech
Events April 18, 2023
MedTech Impact Gala 2023
We are excited to share that we will sponsor and speak at MedTech Impact Symposium 2023.  The Symposium is organized by Massachusetts Medical Device Industry Council (MassMEDIC) and(...)
Medical Devices MedTech
Events April 18, 2023
MedTech Impact Symposium 2023
We are excited to share that we will sponsor and speak at MedTech Impact Symposium 2023.  The Symposium is organized by Massachusetts Medical Device Industry Council (MassMEDIC) and(...)
Medical Devices MedTech
Blog April 17, 2023
Reimbursement of Rare Disease Drugs in Italy: Challenges and Hopes for the Future
When it comes to rare diseases, Italy has done a good job in bringing EMA-approved drugs, including orphan drugs, to the Italian market. But  multiple challenges exist, many of which(...)
Italy Market Access Pharma Rare Disease Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.